BlackRock’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-11,404,974
| Closed | -$68.8M | – | 5167 |
|
|
2019
Q4 | $68.8M | Sell |
11,404,974
-146,682
| -1% | -$849K | ﹤0.01% | 2170 |
|
|
2019
Q3 | $41.6M | Buy |
11,551,656
+148,140
| +1% | +$571K | ﹤0.01% | 2411 |
|
|
2019
Q2 | $30.6M | Sell |
11,403,516
-58,336
| -0.5% | -$172K | ﹤0.01% | 2600 |
|
|
2019
Q1 | $33.9M | Sell |
11,461,852
-639,325
| -5% | -$1.57M | ﹤0.01% | 2500 |
|
|
2018
Q4 | $19.2M | Buy |
12,101,177
+175,818
| +1% | +$497K | ﹤0.01% | 2740 |
|
|
2018
Q3 | $43.9M | Buy |
11,925,359
+61,683
| +0.5% | +$184K | ﹤0.01% | 2448 |
|
|
2018
Q2 | $33.6M | Buy |
11,863,676
+159,694
| +1% | +$544K | ﹤0.01% | 2582 |
|
|
2018
Q1 | $43.4M | Buy |
11,703,982
+131,967
| +1% | +$432K | ﹤0.01% | 2350 |
|
|
2017
Q4 | $33.3M | Buy |
11,572,015
+1,736,124
| +18% | +$6.31M | ﹤0.01% | 2507 |
|
|
2017
Q3 | $44.2M | Buy |
9,835,891
+305,749
| +3% | +$1.36M | ﹤0.01% | 2359 |
|
|
2017
Q2 | $43.7M | Sell |
9,530,142
-378,230
| -4% | -$1.52M | ﹤0.01% | 2341 |
|
|
2017
Q1 | $41.7M | Buy |
9,908,372
+9,853,155
| +17,844% | +$40.9M | ﹤0.01% | 2331 |
|
|
2016
Q4 | $229K | Buy |
55,217
+7,777
| +16% | +$41.3K | ﹤0.01% | 2059 |
|
|
2016
Q3 | $385K | Buy |
47,440
+22,788
| +92% | +$194K | ﹤0.01% | 1844 |
|
|
2016
Q2 | $192K | Buy |
24,652
+16,705
| +210% | +$143K | ﹤0.01% | 2126 |
|
|
2016
Q1 | $61K | Buy |
7,947
+3,925
| +98% | +$28.7K | ﹤0.01% | 2261 |
|
|
2015
Q4 | $43K | Buy |
4,022
+1,148
| +40% | +$10.4K | ﹤0.01% | 2149 |
|
|
2015
Q3 | $20K | Hold |
2,874
| – | – | ﹤0.01% | 2404 |
|
|
2015
Q2 | $26K | Sell |
2,874
-152
| -5% | -$1.44K | ﹤0.01% | 2283 |
|
|
2015
Q1 | $29K | Buy |
3,026
+263
| +10% | +$3.28K | ﹤0.01% | 2192 |
|
|
2014
Q4 | $33K | Sell |
2,763
-22,327
| -89% | -$273K | ﹤0.01% | 2140 |
|
|
2014
Q3 | $250K | Buy |
25,090
+22,202
| +769% | +$206K | ﹤0.01% | 1472 |
|
|
2014
Q2 | $22K | Hold |
2,888
| – | – | ﹤0.01% | 2341 |
|
|
2014
Q1 | $9K | Hold |
2,888
| – | – | ﹤0.01% | 2811 |
|
|
2013
Q4 | $9K | Hold |
2,888
| – | – | ﹤0.01% | 2807 |
|
|
2013
Q3 | $8K | Hold |
2,888
| – | – | ﹤0.01% | 2811 |
|
|
2013
Q2 | $24K | Buy |
+2,888
| New | +$22K | ﹤0.01% | 2215 |
|
BlackRock's ACHN Position: Q1 2020 in Review
BlackRock sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 11,404,974 shares — an estimated $68.8M sold.
BlackRock first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $68.8M in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- BlackRock reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- BlackRock sold 11,404,974 Achillion Pharmaceuticals shares in Q1 2020, an estimated $68.8M.
- BlackRock first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- BlackRock's Achillion Pharmaceuticals position peaked at $68.8M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on BlackRock's 13F filing for Q1 2020, filed 1 May 2020.